$5.30 target price

2347 GMT [Dow Jones] STOCK CALL: RBS raises Biota (BTA.AU) target to A$2.25 from A$1.53 on partner GlaxoSmithKline's (GSK) plans to triple Relenza production capacity to 190 million courses. Also more than trebles FY10 EPS forecast to 53.7 cents and FY11 more than sixfold to 66.7 cents. News on "further government orders and clinical results are expected to maintain investor interest," says RBS. Release of potential positive results for Biota's long-acting version of Relenza and possible approval in time for the Japanese 2011 flu season may help the stock, it says. Keeps at Buy. Last trade A$1.76. (ABH)


(My analysis)- I'm not sure if people realise that according to this if BTA has EPS of 53.7 cents with a P/E of 10 that comes to a share price of $5.36!!!